Ultrasound microbubble contrast agent (DrugBank: -)
1 diseaseID | Disease name (Link within this page) | Number of trials |
---|---|---|
96 | Crohn disease | 1 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03492944 (ClinicalTrials.gov) | March 6, 2020 | 12/2/2018 | Contrast Enhanced Ultrasound in Human Crohn's Disease-Lumason | Contrast-Enhanced Ultrasound Evaluation of Bowel Wall Inflammation in Pediatric Crohn's Disease: Comparison to CT and MRI Enterography | Crohn Disease | Drug: Ultrasound Microbubble Contrast Agent;Device: Ultrasound Imaging | Children's Hospital Medical Center, Cincinnati | NULL | Recruiting | 10 Years | 18 Years | All | 25 | United States |